Loading cancer entity…
Loading cancer entity…
Clinical trials
136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03651375 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall(UN-RESARC) | unknown | Phase 2 | 46 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02343172 | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | completed | Phase 1 | 74 | Novartis PharmaceuticalsINDUSTRY | 6 |
| Dec 9, 2020 |
| clinicaltrials |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | withdrawn | Phase 1 | 0 | Matthew InghamOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03303885 | The FGF/FGFR Signalling Pathway:(FILIPO) | completed | — | 421 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial | completed | Phase 2 | 52 | Grupo Espanol de Investigacion en SarcomasOTHER | 2 | Jul 23, 2020 | clinicaltrials |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | terminated | Phase 2 | 89 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03397186 | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01957709 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | terminated | Early Phase 1 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT03816475 | Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial)(LIPOMYX) | unknown | Phase 2 | 35 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | withdrawn | Phase 3 | 0 | Italian Sarcoma GroupNETWORK | 1 | May 13, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02983539 | Detection of Circulating Tumor Cells in Patients With Sarcomas(CTCS) | unknown | — | 20 | AC Camargo Cancer CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01209598 | PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | completed | Phase 2 | 90 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03096912 | A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | unknown | Phase 2 | 30 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Oct 25, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00356031 | Bevacizumab and Radiation Therapy for Sarcomas | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01537744 | A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma | completed | Phase 1 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT01506596 | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | completed | Phase 2 | 42 | Vector OncologyOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02571829 | A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | unknown | Phase 2 | 30 | Hadassah Medical OrganizationOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT00720174 | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | May 17, 2016 | clinicaltrials |
| NCT01567046 | Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas | completed | — | 70 | Children's Oncology GroupNETWORK | 1 | May 17, 2016 | clinicaltrials |
| NCT02059850 | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT02587169 | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum(GEIS-27) | unknown | Phase 1 / Phase 2 | 40 | Broto, Javier Martín, M.D.INDIV | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00969917 | Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma | withdrawn | Phase 2 | 0 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 14, 2015 | clinicaltrials |
| NCT00233948 | Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma | terminated | Phase 1 / Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00093080 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT01426633 | Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas | completed | Phase 1 | 5 | Heidelberg UniversityOTHER | 1 | Dec 16, 2014 | clinicaltrials |
| NCT01477021 | Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 11, 2014 | clinicaltrials |
| NCT00060944 | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | completed | Phase 2 | 271 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 8 | Sep 8, 2014 | clinicaltrials |
| NCT00132704 | An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation | completed | — | 149 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2014 | clinicaltrials |
| NCT00579501 | Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | completed | Phase 2 | 29 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 3 | May 7, 2014 | clinicaltrials |
| NCT00400569 | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 28, 2012 | clinicaltrials |
| NCT00633165 | Brostallicin Clinical Trial for Myxoid Liposarcoma(SMI-BRS-202) | unknown | Phase 2 | 24 | Systems Medicine LLCINDUSTRY | 1 | Feb 26, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Jan 22, 2021source: clinicaltrials